Cas9 Stable Cell Line - Caco-2

The Cas9 Stable Cell Line – Caco-2 is a genetically engineered human cell line derived from colorectal adenocarcinoma cells. Caco-2 cells naturally differentiate into intestinal epithelial-like cells under standard culture conditions, making it the gold standard for mimicking the human intestinal barrier. This stable cell line integrates CRISPR-Cas9 technology via lentiviral transduction, ensuring stable expression of the Cas9 endonuclease. Its key characteristics include robust proliferation, epithelial cell morphology, and the ability to form tight junctions mimicking intestinal epithelial cells. Cas9 integration allows for precise genome editing without repeated transfections, significantly improving experimental reproducibility. These cells maintain high viability and stable Cas9 expression after multiple passages, making them ideal for long-term genetic studies.

The Cas9 Stable Cell Line - Caco-2 has transformative applications in drug and biomedical research. It primarily accelerates drug discovery by enabling high-throughput screening of compounds for permeability, absorption, and toxicity through Caco-2 monolayers. Caco-2 monolayers are a key model for predicting the bioavailability of orally administered drugs. Researchers used CRISPR-Cas9 technology to knock out genes involved in drug transport proteins (such as P-glycoproteins) or metabolic enzymes, thereby elucidating the mechanisms of drug interactions and intestinal efflux. In disease modeling, scientists constructed precise mutation models by targeting CFTR gene variants to study the pathogenesis of colorectal cancer, inflammatory bowel disease, or cystic fibrosis and other hereditary diseases. This cell line can also be used for functional genomics screening to identify novel therapeutic targets for gastrointestinal cancers using mixed sgRNA libraries.